The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis.
Angelo ZinelluClaudia ColluMouhamad NasserPanagiotis PaliogiannisSabrina MellinoElisabetta ZinelluJulie TracletKais AhmadArduino Aleksander MangoniCiriaco CarruPietro PirinaAlessandro Giuseppe FoisVincent CottinPublished in: Journal of clinical medicine (2021)
Variable patterns of disease progression are typically observed in patients with idiopathic pulmonary fibrosis (IPF). We sought to determine the prognostic capacity of blood cell count indexes, derived from routine complete blood cell (CBC) count, in a cohort of IPF patients. The neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were calculated at baseline in a consecutive series of 82 IPF patients followed for four years. After adjusting for age, gender, body mass index, smoking status, and disease stage, only the AISI was significantly associated with mortality (HR 1.0013, 95% CI 1.0003-1.0023, p = 0.015). Patients with AISI <434 and ≥434 had a median survival from the diagnosis of 35.3 ± 15.2 and 26.6 ± 16.3 months (p = 0.015), and a four-year survival rate of 54% and 34%, respectively. The AISI, easily derivable from routine laboratory tests, is independently associated with mortality in patients with IPF. Prospective studies in larger cohorts are required to confirm this association.
Keyphrases
- idiopathic pulmonary fibrosis
- end stage renal disease
- interstitial lung disease
- body mass index
- newly diagnosed
- chronic kidney disease
- ejection fraction
- single cell
- cardiovascular disease
- risk factors
- dendritic cells
- stem cells
- rheumatoid arthritis
- coronary artery disease
- immune response
- patient reported
- free survival
- weight loss